Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GELS NASDAQ:LEXX NASDAQ:PALI NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGELSGelteq$1.62-6.4%$1.82$0.77▼$5.50$16.33MN/A189,349 shs66,557 shsLEXXLexaria Bioscience$0.85-5.5%$0.94$0.79▼$4.38$17.60M0.79188,367 shs243,257 shsPALIPalisade Bio$1.01-1.0%$0.79$0.60▼$4.32$4.89M1.341.14 million shs192,191 shsVYNEVYNE Therapeutics$0.35-3.5%$1.14$0.34▼$4.30$5.56M1.762.79 million shs2.94 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGELSGelteq-6.36%-15.18%-7.43%-12.43%+161,999,900.00%LEXXLexaria Bioscience-5.52%-13.06%-0.57%-28.55%-79.21%PALIPalisade Bio-0.98%-12.93%+38.45%+27.46%-74.23%VYNEVYNE Therapeutics-3.47%-75.83%-76.63%-74.24%-81.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGELSGelteqN/AN/AN/AN/AN/AN/AN/AN/ALEXXLexaria Bioscience2.6891 of 5 stars3.52.00.00.01.83.30.6PALIPalisade Bio2.6816 of 5 stars3.54.00.00.01.90.01.3VYNEVYNE Therapeutics2.5133 of 5 stars3.05.00.00.01.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGELSGelteq 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$4.00370.42% UpsidePALIPalisade Bio 3.00Buy$12.001,088.12% UpsideVYNEVYNE Therapeutics 2.00Hold$6.251,671.04% UpsideCurrent Analyst Ratings BreakdownLatest PALI, LEXX, VYNE, and GELS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025VYNEVYNE TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/30/2025VYNEVYNE TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/30/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.005/13/2025PALIPalisade BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGELSGelteq$100K152.93N/AN/A$1.30 per share1.25LEXXLexaria Bioscience$460K36.16N/AN/A$0.26 per share3.27PALIPalisade Bio$250K19.39N/AN/A$2.71 per share0.37VYNEVYNE Therapeutics$500K10.74N/AN/A$3.53 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/ALEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/APALIPalisade Bio-$14.44M-$6.80N/AN/AN/AN/A-178.96%-127.35%8/11/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)Latest PALI, LEXX, VYNE, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VYNEVYNE Therapeutics-$0.24N/AN/AN/A$0.15 millionN/A8/11/2025Q2 2025PALIPalisade Bio-$0.48N/AN/AN/AN/AN/A7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million5/12/2025Q1 2025PALIPalisade Bio-$0.84-$0.47+$0.37-$0.47N/AN/A5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGELSGelteqN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGELSGelteqN/A0.79N/ALEXXLexaria BioscienceN/A3.903.90PALIPalisade BioN/A2.842.84VYNEVYNE TherapeuticsN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGELSGelteqN/ALEXXLexaria Bioscience13.06%PALIPalisade Bio11.79%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipGELSGelteqN/ALEXXLexaria Bioscience26.40%PALIPalisade Bio3.28%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGELSGelteqN/A9.44 millionN/AN/ALEXXLexaria Bioscience719.56 million14.40 millionNot OptionablePALIPalisade Bio104.80 million4.64 millionNot OptionableVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionablePALI, LEXX, VYNE, and GELS HeadlinesRecent News About These CompaniesVYNE Therapeutics (NASDAQ:VYNE) Lowered to "Neutral" Rating by HC Wainwright1 hour ago | americanbankingnews.comHere's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash WiselyAugust 1 at 4:19 AM | finance.yahoo.comRepibresib gel fails to meet endpoints for nonsegmental vitiligo studyAugust 1 at 4:19 AM | healio.comHVyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental VitiligoJuly 31 at 3:02 AM | marketwatch.comVYNE Therapeutics stock falls after vitiligo trial fails to meet endpointsJuly 31 at 3:02 AM | za.investing.comHC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)July 31 at 3:02 AM | msn.comVYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary EndpointJuly 31 at 3:02 AM | appliedclinicaltrialsonline.comAVYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint MissedJuly 31 at 3:02 AM | marketwatch.comVyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stockJuly 31 at 3:02 AM | fiercebiotech.comFVyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye ReboundJuly 31 at 3:02 AM | msn.comVYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental VitiligoJuly 30 at 8:00 AM | globenewswire.comVYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.7% - Here's What HappenedJuly 30 at 2:39 AM | americanbankingnews.comVyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b ReadoutJuly 28, 2025 | seekingalpha.comVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressJuly 11, 2025 | insidermonkey.comVyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitorJuly 2, 2025 | fiercebiotech.comFVYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis TrialJuly 2, 2025 | quiverquant.comQVYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202July 2, 2025 | globenewswire.comVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, LEXX, VYNE, and GELS Company DescriptionsGelteq NASDAQ:GELS$1.62 -0.11 (-6.36%) As of 08/1/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Lexaria Bioscience NASDAQ:LEXX$0.85 -0.05 (-5.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.85 0.00 (-0.39%) As of 08/1/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Palisade Bio NASDAQ:PALI$1.01 -0.01 (-0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.99%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.VYNE Therapeutics NASDAQ:VYNE$0.35 -0.01 (-3.47%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.60%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
